Developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection. By leveraging the natural power of the immune response system, we are able to utilize fusion protein technology to attack difficult tumor targets throughout the body. Focus/Therapeutic Area: Oncology Stage/Status: Seed Website:

XenImmune Read More »

Tasca Therapeutics

With a novel approach to precision oncology, Tasca Therapeutics is unlocking post-translational modification of proteins by utilizing our state-of-the-art chemical biology and computational approaches, and combining with inhibition at key metabolic nodes to generate drugs for previously considered undruggable targets. Tasca is focused on using its proprietary platform to develop small molecule drugs for hard-to-treat

Tasca Therapeutics Read More »